Literature DB >> 17542528

Gamma knife surgery for trigeminal schwannoma.

Jason Sheehan1, Chun Po Yen, Yasser Arkha, David Schlesinger, Ladislau Steiner.   

Abstract

OBJECT: Trigeminal schwannomas are rare intracranial tumors. In the past, resection and radiation therapy were the mainstays of their treatment. More recently, neurosurgeons have begun to use radiosurgery in the treatment of trigeminal schwannomas because of its successful use in the treatment of vestibular schwannomas. In this article the authors evaluate the radiological and clinical outcomes in a series of patients in whom Gamma Knife surgery (GKS) was used to treat trigeminal schwannomas.
METHODS: Twenty-six patients with trigeminal schwannomas underwent GKS at the University of Virginia Lars Leksell Gamma Knife Center between 1989 and 2005. Five of these patients had neurofibromatosis and one patient was lost to follow up. The median tumor volume was 3.96 cm(3), and the mean follow-up period was 48.5 months. The median prescription radiation dose was 15 Gy, and the median prescription isodose configuration was 50%. There was clinical improvement in 18 patients (72%), a stable lesion in four patients (16%), and worsening of the disease in three patients (12%). On imaging, the schwannomas shrank in 12 patients (48%), remained stable in 10 patients (40%), and increased in size in three patients (12%). These results were comparable for primary and adjuvant GKSs. No tumor growth following GKS was observed in the patients with neurofibromatosis.
CONCLUSIONS: Gamma Knife surgery affords a favorable risk-to-benefit profile for patients harboring trigeminal schwannomas. Larger studies with open-ended follow-up review will be necessary to determine the long-term results and complications of GKS in the treatment of trigeminal schwannomas.

Entities:  

Mesh:

Year:  2007        PMID: 17542528     DOI: 10.3171/jns.2007.106.5.839

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  7 in total

Review 1.  Stereotactic body radiotherapy for benign spinal tumors: Meningiomas, schwannomas, and neurofibromas.

Authors:  Lindsay Hwang; Christian C Okoye; Ravi B Patel; Arjun Sahgal; Matthew Foote; Kristin J Redmond; Christoph Hofstetter; Rajiv Saigal; Mahmud Mossa-Basha; William Yuh; Nina A Mayr; Samuel T Chao; Eric L Chang; Simon S Lo
Journal:  J Radiosurg SBRT       Date:  2019

2.  Trigeminal schwannomas: experience with 57 cases and a review of the literature.

Authors:  Raita Fukaya; Kazunari Yoshida; Takayuki Ohira; Takeshi Kawase
Journal:  Neurosurg Rev       Date:  2010-10-21       Impact factor: 3.042

3.  Stereotactic radiosurgery: a meta-analysis of current therapeutic applications in neuro-oncologic disease.

Authors:  Susan C Pannullo; Justin F Fraser; Jennifer Moliterno; William Cobb; Philip E Stieg
Journal:  J Neurooncol       Date:  2010-12-09       Impact factor: 4.130

4.  Clinical and Imaging Response to Trigeminal Schwannoma Radiosurgery: A Retrospective Analysis of a 28-Year Experience.

Authors:  Ajay Niranjan; Sudesh S Raju; Hideyuki Kano; John C Flickinger; Lawrence Dade Lunsford
Journal:  J Neurol Surg B Skull Base       Date:  2020-08-14

5.  Multimodality Management of Trigeminal Schwannomas.

Authors:  Ajay Niranjan; Samuel Barnett; Vijay Anand; Siviero Agazzi
Journal:  J Neurol Surg B Skull Base       Date:  2016-04-22

6.  Thirty-year clinical experience in gamma knife radiosurgery for trigeminal schwannomas.

Authors:  Dong-Won Shin; Chunseng Ju; Hyun Seok Lee; Hee Jun Yoo; Sang Woo Song; Young Hyun Cho; Chang-Ki Hong; Seok Ho Hong; Do Heui Lee; Jeong Hoon Kim; Young-Hoon Kim
Journal:  Sci Rep       Date:  2022-08-23       Impact factor: 4.996

Review 7.  Tumor control and trigeminal dysfunction improvement after stereotactic radiosurgery for trigeminal schwannomas: a systematic review and meta-analysis.

Authors:  Iulia Peciu-Florianu; Jean Régis; Marc Levivier; Michaela Dedeciusova; Nicolas Reyns; Constantin Tuleasca
Journal:  Neurosurg Rev       Date:  2020-11-13       Impact factor: 3.042

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.